Lux, M P., Wöckel, A., Benedict, A., Buchholz, S., Kreif, N., Harbeck, N., Kreienberg, R., Kaufmann, M., Beckmann, M W., Jonat, W., Hadji, P., Distler, W., Raab, G., Tesch, H., Weyers, G., Possinger, K., & Schneeweiss, A. (2010). Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – a Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System. Basel: Karger.
ISBD ZitierstilCost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – a Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System . — Basel : Karger, 2010
MLA ZitierstilLux, Michael P., et al. Cost-Effectiveness Analysis of Anastrozole Versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – a Health-Economic Analysis Based On the 100-Month Analysis of the ATAC Trial and the German Health System.Basel: Karger, 2010.